Reponse to letter Re: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study

EJC Skin Cancer 2026 Open access

Read full text
Authors: Michael Weichenthal, Eva Ellebæk
DOI: 10.1016/j.ejcskn.2026.101149
Cited by: 1
References: 2

Fields of Study & Subjects

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Lung Cancer Treatments and Mutations

Publication details

Journal / source
EJC Skin Cancer
Publisher
Elsevier BV
Volume
4
Pages
101149–101149
Publication date
1 January 2026
Language
EN